ストックスクリーナーアプリを入手
42.63
2.89%
-1.27
アフターアワーズ：
42.70
0.07
+0.16%
Definium Therapeutics Inc (DFTX) 最新ニュース
DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push? - Stocktwits
DFTX Stock Clocks Best Day In Over Two Years On 'Best-Case' Clinical Results For Oral Lysergide In Depression - Stocktwits
Top Definium Therapeutics (DFTX) Competitors 2026 - MarketBeat
DFTX Maintained by Maxim Group -- Price Target Raised to $55 - GuruFocus
Definium Therapeutics Price Target Raised to $55.00/Share From $50.00 by Maxim Group - moomoo.com
Definium Therapeutics (DFTX): Commodore Capital discloses 2.41M-share, 1.8% beneficial stake - Stock Titan
Definium Therapeutics' Voyage Trial Success Reshapes Valuation Debate for Anxiety Drug - finance.biggo.com
DFTX News Today | Why did Definium Therapeutics stock go down today? - MarketBeat
Driehaus Capital trims percentage stake in Definium Therapeutics (DFTX) to 5.36% - Stock Titan
Definium Therapeutics (DFTX) Voyage Data Puts Valuation Back In Focus - Yahoo Finance
Definium Therapeutics' DT120 Data Boosts Confidence in Future Trials, RBC Capital Markets Says - Moomoo
Is Successful Voyage Phase 3 Data Transforming the Investment Case For Definium Therapeutics (DFTX)? - Yahoo Finance
DFTX Maintained by Jones Trading -- Price Target Raised to $90.0 - GuruFocus
Definium says LSD-based pill reduces anxiety in late-stage study - Reuters
Definium Therapeutics (NASDAQ:DFTX) Price Target Raised to $90.00 at JonesTrading - MarketBeat
DFTX Maintained by Canaccord Genuity -- Price Target Raised to $64 - GuruFocus
Definium Therapeutics (DFTX) Hits Phase 3 GAD Goals For DT120 ODT - Yahoo Finance
DFTX Maintained by RBC Capital -- Price Target Raised to $66.00 - GuruFocus
Royal Bank Of Canada Forecasts Strong Price Appreciation for Definium Therapeutics (NASDAQ:DFTX) Stock - MarketBeat
DFTX Maintained by Wells Fargo -- Price Target Raised to $72 - GuruFocus
Definium Therapeutics (NASDAQ:DFTX) Price Target Raised to $72.00 at Wells Fargo & Company - MarketBeat
JonesTrading Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $90 - moomoo.com
Definium Phase III success with DT120 in anxiety - The Pharma Letter
Robert W. Baird Increases Definium Therapeutics (NASDAQ:DFTX) Price Target to $75.00 - MarketBeat
Canaccord raises Definium Therapeutics price target on trial data By Investing.com - Investing.com Australia
Canaccord raises Definium Therapeutics price target on trial data - Investing.com
DFTX Maintained by Baird -- Price Target Raised to $75.00 - GuruFocus
RBC Adjusts PT on Definium Therapeutics to $66 From $57, Keeps Outperform Speculative Risk Rating - marketscreener.com
Definium Therapeutics’ DT120 Meets Phase III Goals in GAD Study - MarketBeat
What Do Definium Therapeutics (DFTX) Phase 3 GAD Results Mean For DT120? - Sahm
Definium Therapeutics: 'Strong Buy' On Positive DT120 ODT Data, Two Indications, And September 2026 Catalyst - Seeking Alpha
DFTX Maintained by Needham -- Price Target Raised to $66.00 - GuruFocus
Needham & Company LLC Raises Definium Therapeutics (NASDAQ:DFTX) Price Target to $66.00 - MarketBeat
DFTX Stock Rallies As Psychedelic Drug Delivers Positive Anxiety Trial Results — Retail Says DT120 Could ‘Disrupt The Market’ - TradingView
Definium Therapeutics (NASDAQ:DFTX) Shares Gap UpWhat's Next? - MarketBeat
Definium Therapeutics CEO Robert Barrow Acquires 375,000 Shares via Performance Share Units - Kalkine Media
Definium Therapeutics Says Unprecedented Efficacy From Anxiety Study 'Raises the Bar' - Benzinga
Definium Therapeutics Announces Positive Phase 3 Voyage Topline Results for DT120 ODT - Kalkine Media
Definium Therapeutics (DFTX) Shares Surge After Positive Phase 3 Trial; Valuation Hinges on Future Growth - GuruFocus
Form 8K Definium Therapeutics Inc For: 12 August By Investing.com - Investing.com Canada
Definium Therapeutics stock jumps 20% on Phase 3 trial results By Investing.com - Investing.com Canada
Definium Therapeutics (DFTX) awards 62,500 performance-based shares to Chief Commercial Officer - Stock Titan
Definium Therapeutics (DFTX) awards CEO 375,000 performance-based shares - Stock Titan
Definium Therapeutics (DFTX) CFO receives 62,500-share performance-based equity grant - Stock Titan
Definium Therapeutics (DFTX) CLO awarded 62,500 performance-based shares in PSU tranche - Stock Titan
Wondering what's happening in today's pre-market session? - ChartMill
Definium Therapeutics posts positive Phase 3 Voyage topline: DT120 ODT cuts HAM-A by 5.4 pts vs placebo - TradingView
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Definium Therapeutics (Nasdaq: DFTX) reports positive DT120 GAD Phase 3 data - Stock Titan
Definium Therapeutics shares surge after positive Phase 3 anxiety trial results - Yahoo Finance
Definium Says DT120 Phase 3 GAD Study Shows 5.4-Point HAM-A Benefit vs Placebo - marketscreener.com
Definium Therapeutics stock jumps 20% on Phase 3 trial results - Investing.com
Definium reports positive phase 3 results for anxiety drug By Investing.com - Investing.com UK
Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of Dt120 Odt in Generalized Anxiety Disorder - marketscreener.com
Research Analysts Set Expectations for DFTX Q3 Earnings - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):